S73
Brachytherapy - Gynaecology
ESTRO 2026
Consequently, guidance is urgently needed to minimise unnecessary brachytherapy deferrals and variation in systematic target definition approach that
induction chemotherapy could cause. Keywords: induction chemotherapy References:
1: Pötter R, Tanderup K, Schmid MP, et al. EMBRACE II - a multicenter prospective interventional cohort study on IGRT-IMRT+cisplatin+MR-IGABT in locally advanced cervix cancer: overall results,Radiotherapy and Oncology May 2025;206(Suppl 1): S837-S840,2: McCormack M, Eminowicz G, Gallardo D, et al. Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial. The Lancet. 2024 Oct;404(10462):1525–35. Clinical Results of Image-Guided Adaptive Brachytherapy After Chemoradiotherapy for Cervical Cancer: Experience from Hospital Carlos Van Buren, Chile María José Maluk Alarcón 1 , Francisco Pérez Peña 1 , Gabriel Lazcano Álvarez 2,1 , Darlett Folch Mora 1 , Maximiliano Reyes Escobar 1 , Tomás Walter Martin 1 , Josefa Giusti-Bilz Schäfer 3 , Gonzalo Lanza Prüssing 3 , Gabriel Veillón Contreras 2,1 , Anaís Molina Cárcamo 3 , José Solís Campos 2,1 1 Oncology, Universidad de Valparaíso, Valparaíso, Chile. 2 Radation Oncology Department, Hospital Carlos Van Buren, Valparaíso, Chile. 3 School of Medicine, Universidad de Valparaíso, Valparaíso, Chile Purpose/Objective: Concurrent chemoradiotherapy followed by image- guided adaptive brachytherapy (IGABT) is the standard treatment for patients with locally advanced cervical cancer [1,2]. The purpose of this study is to describe the outcomes of the IGABT protocol from an oncology department within the Chilean public health-care network. Material/Methods: This retrospective cohort study included patients treated with curative intent between 2019 and 2024 for cervical cancer. Patients received 3DCRT- or VMAT- based chemoradiotherapy, delivering 45 Gy in 25 fractions to the pelvis (from the iliac bifurcation) and up to 57.5 Gy boosts to involved lymph nodes, without prophylactic para-aortic coverage, followed by IGABT with a high-dose-rate (HDR) source. The prescribed Digital Poster 3613 total dose aimed for an equivalent dose in 2 Gy fractions (EQD2) of 83.6 Gy to the high-risk clinical target volume (HR-CTV). The study was approved by
Conclusion: This limited survey confirms expected brachytherapy practice variation. Most centers use induction chemotherapy but only regularly in the minority. When used, brachytherapy deferrals occur, with variable parameters to trigger deferrals and variation of reference imaging for target definition.
Made with FlippingBook - Share PDF online